Prognostic factors in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with severe glomerular sclerosis: a national registry-based cohort study by Bjørneklett, Rune et al.
Research Article
Prognostic Factors in Anti-Neutrophil
Cytoplasmic Antibody-Associated Glomerulonephritis
with Severe Glomerular Sclerosis: A National
Registry-Based Cohort Study
Rune Bjørneklett ,1,2 Vilde Solbakken ,1 Leif Bostad ,3 and Anne-Siri Fismen4
1Department of Clinical Medicine, University of Bergen, Bergen, Norway
2Emergency Care Clinic, Haukeland University Hospital, Bergen, Norway
3Department of Pathology, Haukeland University Hospital, Bergen, Norway
4Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Bergen, Norway
Correspondence should be addressed to Rune Bjørneklett; rune.bjoerneklett@helse-bergen.no
Received 7 January 2018; Revised 17 March 2018; Accepted 3 April 2018; Published 3 June 2018
Academic Editor: Maria M. Picken
Copyright © 2018 RuneBjørneklett et al.This is an open access article distributed under theCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Classification of patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN) into
histological classes is useful for predicting a patient’s risk of progression to end-stage renal disease (ESRD). However, even in the
worst prognostic group, the 5-year end-stage renal disease-free survival rate is as high as 50%. Objectives. To investigate those
prognostic factors indicative of progression to ESRD in patients with ANCA-GN and sclerosing histology.Methods. Patients from
the Norwegian Kidney Biopsy Registry between 1991 and 2012 who had biopsy verified pauci-immune glomerulonephritis, positive
ANCA serology, and sclerosing histology were included. Cases with ESRD during follow-up were identified via linkage with
the Norwegian Renal Registry. Potential prognostic factors with relevant cut-offs were compared in patients with and without
progression to ESRD during follow-up. Results. Of 23 included patients, 10 progressed to ESRD. ESRD patients had a lower initial
estimated glomerular filtration rate (eGFR; 21 versus 52ml/min/1.73m2) and a lower percentage of normal glomeruli (4% versus
15%). Five-year risks of ESRDwith eGFR>15 versus≤15ml/min/1.73m2 were 77% and 15%, with percentage normal glomeruli>10%
versus ≤10%, 83% and 39%. Conclusions. eGFR and percentage of normal glomeruli are strong risk factors for ESRD in ANCA-GN
with sclerosing histology.
1. Introduction
Renal involvement in the form of glomerulonephritis is
common and associated with increased morbidity and mor-
tality in patients with anti-neutrophil cytoplasmic antibody-
(ANCA-) associated vasculitis (AAV) [1–3]. A clinical pre-
sentation involving rapidly progressive glomerulonephritis
syndromewith a positive ANCA test is diagnostic for ANCA-
associated glomerulonephritis (ANCA-GN), but tissue con-
firmation by kidney biopsy is preferred whenever feasible
[4, 5]. In addition to confirming the diagnosis of ANCA-
GN, histological analysis yields important prognostic infor-
mation [6–13]. In 2010, an international consortium of renal
pathologists and nephrologists proposed a histopathological
classification schema for ANCA-GN, which consisted of four
histological classes: focal (≥50% normal glomeruli), crescen-
tic (≥50% glomeruli with cellular crescents), mixed (<50%
normal/crescentic/globally sclerotic glomeruli), and sclerotic
(≥50 globally sclerotic glomeruli) [14]. This classification
model’s capacity to predict end-stage renal disease (ESRD)
has now been validated in many different cohorts of patients
with ANCA-GN [15–30]. Generally, focal histology is found
to be associated with the best outcomes, whereas a sclerotic
histology is associated with the poorest prognosis. Mean-
while, the prognostic separation of patients with crescentic
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versus mixed histology is based on results from various
validation studies not particularly useful [16, 31].
Generally, the most clinically valuable prognostic models
are those that can be used to guide physicians regarding
treatment and follow-up regimens for patients [31, 32]. If left
untreated, a patient with ANCA-GN has a very poor prog-
nosis [33]. With adequate treatment, progression to ESRD
can be avoided in most patients with focal/crescentic/mixed
histology and there are currently no data suggesting that
different therapeutic approaches should be used for these
groups. In patients with ANCA-GN and a sclerotic histologi-
cal presentation, one could speculatewhether, due to substan-
tial irreversible renal damage, a less intensive/toxic treatment
regimen would benefit patients. However, data from several
studies shows that an ESRD-free survival rate in patients
with sclerotic histology is surprisingly high, being nearly
50% at 5 years [16]. Thus, reducing treatment intensity in
cases with a sclerotic histological presentation could deprive
many patients from a successful treatment outcome. There
are theoretically many causes of the variability in outcomes
of patients with ANCA-GN and sclerotic histology. First, the
biopsy needle might have hit a fibrotic scar in the kidney that
is otherwise not representative of the total renal mass of the
particular patient. Second, the formal criterion for sclerotic
histology is at least 50% globally sclerotic glomeruli, which
allows for 0–49%of normal and/or crescentic glomeruli. Such
flexibility in possible histology under this criterion could
contribute to the considerable variation in patient outcomes.
Here, using data from the Norwegian Kidney Biopsy
Registry (NKBR) and the Norwegian Renal Registry, we have
analyzed predictive factors that could be used to stratify
patients with ANCA-GN and a sclerotic histological picture
based upon risk. Our hypothesis is that such risk stratification
is feasible and could increase the clinical utility of histological
classification in patients with ANCA-GN.
2. Materials and Methods
The Regional Committee for Medical and Health Research
Ethics (REC South-East) approved this study.
In the present study, we included patients with ANCA-
GN and a sclerotic histological presentation, as previously
described [16]. Identification of the study cohort, baseline
data, scoring of patients according to the histologic classifi-
cationmodel of ANCA-GN, definition of observation period,
and end-points have been described in detail earlier and are
only briefly reviewed here.
We identified all patients with a biopsy verified ANCA-
GN in the NKBR from 1991 to 2012. The criteria for
ANCA-GN were the finding of a pauci-immune necrotizing
glomerulonephritis and a positive ANCA titer. Baseline data,
including sex, age, ANCA serotype, estimated GFR (eGFR),
serum-albumin, systolic and diastolic blood-pressure, and
proteinuria, were obtained from the NKBR. An experienced
renal-pathologist (L.B.) classified all cases according to the
histological classification schema of ANCA-GN and those
with a sclerotic presentation and at least 10 glomeruli available
for analysis were included in the present study cohort. The
pathologist also counted for the percentage of glomeruli
without global sclerosis or crescents present in each case.The
observation period was from time of biopsy to first event,
ESRD, death, or the end of the study period 31 December
2012. Further, the observation period was stratified into
induction (≤1 year after biopsy) and remission (>1 year after
biopsy) phases. The primary end-point of this study was
ESRD, defined as the initiation of chronic renal replacement
therapy in the form of dialysis or renal transplantation. Cases
with ESRD were identified by linkage of the study cohort
with the Norwegian Renal Registry. The secondary end-
point included death in patients without ESRD, which was
identified by linkage of the study cohort with the Population
Registry of Norway. We also defined a combined end-point
of patients with ESRD or death during follow-up, whichever
came first.
We first compared baseline data between patients who
survived and those who progressed to ESRD or died during
the induction phase. To assess the significance of our findings,
the Chi-squared test was used for categorical variables and
Mann–Whitney 𝑈 test was used for continuous variables.
Second, using Kaplan Meier statistics and log rank tests we
analyzed as 1- and 5-year cumulative ESRD-free survival in
the whole cohort and after stratification based on baseline
eGFR (≤15ml/>15ml/min/1.73m2) and baseline percentage
glomeruli without global sclerosis or crescents in the biopsy
(≤10%/>10%). These analyses were then repeated using the
secondary end-point, ESRD, or death. SPSS version 24 was
used for statistical analyses.
3. Results
Twenty-three patients with a mean age of 58 years (SD =
21) were included in this study. Of these subjects, 13 (57%)
were female. Eighteen (78%) were perinuclear (P) ANCA-
or myeloperoxidase (MPO) ANCA-positive and had a mean
eGFR of 36ml/min/1.73m2 (SD = 40) and amean percentage
glomeruli without crescents or global sclerosis of 9% (SD
= 12%). Other baseline characteristics are shown in Table 1.
The median observation period was 0.7 years (25th–75th
percentiles = 0.1–5.3 years) and there were 74 patient years in
total. As shown in Figure 1, during the short follow-up period
(≤1 year), 9 (39%) patients received chronic renal replacement
therapy and 3 (13%) patients without ESRD had died. Eleven
(48%) patients survived >1 year after the diagnosis of ANCA-
GN without ESRD, 1 (4%) later progressed to ESRD, and 10
(43%) were alive without ESRD by the end of 2012.
A comparison of baseline characteristics between the 11
patients surviving at 1 year after an ANCA-GN diagnosis
without ESRD (survivors) and the 12 patients who progressed
to ESRD or died is shown in Table 1. The following baseline
characteristics differed significantly between survivors and
nonsurvivors: eGFR: 52 versus 21ml/min/1.73m2; serum-
albumin: 41 versus 31 g/L; and percentage normal glomeruli:
14 versus 7.
Cumulative survival at 1 and 5 years without ESRD and
ESRD/death in the study cohort and also after stratification
for baseline eGFR and percentage of normal glomeruli is
shown in Tables 2 and 3. The rate of 1- and 5-year cumulative
survival without ESRD in the whole study cohort was 58%
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Figure 1: Flow chart demonstrating outcomes in the study cohort. ESRD: end-stage renal disease.
Table 1: Baseline characteristics in the total cohort and stratified for living patients without end-stage renal disease at the 1-year follow-up.
Characteristic All, 𝑛 = 23 Alive without ESRD 1-yr, 𝑛 = 11 ESRD/death 1-yr, 𝑛 = 12 𝑝
Females (%) 13 (57%) 5 (45%) 8 (67%) 0.31
Mean age year (SD) 58 (21) 52 (21) 63 (21) 0.13
P-ANCA/MPO-ANCA (%) 18 (78%) 8 (73%) 10 (83%) 0.54
eGFR ml/min/1.73m2 (SD) 36 (40) 52 (43) 21 (32) 0.007
Serum-albumin gram/liter (SD) 36 (10) 41 (11) 31 (5) 0.004
Systolic blood pressure mmHg (SD) 146 (26) 144 (28) 148 (24) 0.40
Diastolic blood pressure mmHg (SD) 80 (11) 80 (12) 79 (10) 0.65
Proteinuria gram/24 hours (SD) 2.2 (2.0) 3.4 (2.4) 2.0 (1.6) 0.95
Percentage normal glomeruli (SD) 9 (12) 15 (14) 4 (7) 0.02
ESRD: end-stage renal disease; yr: year; eGFR: estimated glomerular filtration rate.
Table 2: End-stage free survival at 1 and 5 years of follow-up in the total cohort and stratified according to baseline estimated glomerular
filtration rate and percentage normal glomeruli, as indicated during biopsy.
Characteristic 𝑁 ESRD 1-yr 5-yr 𝑝 value
All 23 10 58% 53%
eGFR ≤ 15ml/min/1.73 9 7 15% 15%
𝑝 = 0.003
eGFR > 15ml/min/1.73 14 3 85% 77%
Normal glomeruli ≤ 10% 16 9 39% 39%
𝑝 = 0.047
Normal glomeruli > 10% 7 1 100% 83%
ESRD: end-stage renal disease; yr: year; eGFR: estimated glomerular filtration rate.
Table 3: End-stage free patient survival at 1 and 5 years of follow-up in total cohort and stratified according to baseline estimated glomerular
filtration rate and percentage normal glomeruli, as indicated during biopsy.
Characteristic 𝑛 ESRD/Death 1-yr 5-yr 𝑝 value
All 23 13 48% 44%
eGFR ≤ 15ml/min/1.73 9 8 11% 11%
𝑝 = 0.006
eGFR > 15ml/min/1.73 14 5 71% 64%
Normal glomeruli ≤ 10% 16 11 31% 31%
𝑝 = 0.054
Normal glomeruli > 10% 7 2 86% 71%
ESRD: end-stage renal disease; yr: year; eGFR: estimated glomerular filtration rate.
and 53%, respectively, whereas those rates after analyzing the
combined end-point ESRD/death were 48% and 44%, respec-
tively. Cumulative survival at 1- and 5-years without ESRD
in patients with a baseline eGFR ≤15/>15ml/min/1.73m2
was 15%/85% (𝑝 = 0.002) and 15%/77% (𝑝 = 0.003),
respectively. For the combined end-point ESRD/death event-
free survival was 11%/71% (𝑝 = 0.004) and 11%/64% (𝑝 =
0.006), respectively. The corresponding numbers obtained
after stratification of the study cohort according to the
percentage of normal glomeruli ≤10%/>10% were 39%/100%
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Figure 2: (a) Kaplan Meier plot demonstrating end-stage renal disease-free survival according to baseline estimated glomerular filtration
rate ≤ versus >15ml/min/1.73m2. (b) Kaplan Meier plot demonstrating end-stage renal disease-free patient survival according to baseline
estimated glomerular filtration rate ≤ versus >15ml/min/1.73m2.
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Figure 3: (a) Kaplan Meier plot demonstrating end-stage renal disease-free survival according to baseline percentage normal glomeruli ≤
versus >10%. (b) Kaplan Meier plot demonstrating end-stage renal disease-free patient survival according to baseline percentage normal
glomeruli ≤ versus >10%.
(ESRD, 𝑝 = 0.02) and 31%/86% (ESRD/death, 𝑝 = 0.02)
at 1-year, respectively. Five-year cumulative survival was
39%/83% (ESRD, 𝑝 = 0.047) and 31%/71% (ESRD/death,
𝑝 = 0.054), respectively. One-year ESRD and ESRD/death
free survival in the study cohort stratified for eGFR≤15 versus
>15ml/min/1.73m2 and percentage normal glomeruli ≤10
versus >10% is shown in Figures 2(a)-2(b) and 3(a)-3(b).
4. Discussion
In the present study, we have shown that it is possible to risk
stratify patients with ANCA-GN and a sclerotic histological
presentation according to their risk of developing ESRD. We
have found that ESRD-free long-term survival is particu-
larly low in patients with sclerotic histology along with an
eGFR ≤ 15ml/min/1.73m2. Meanwhile, patients with eGFR
>15ml/min/1.73m2 at baseline had a much better long-term
ESRD-free survival rate; their prognosis is approximately
within the same range as that previously found for patients
with amixed or a crescentic histological pattern.We therefore
suggest that an eGFR ≤ 15ml/min/1.73m2 represents the
threshold for defining patients with sclerotic histology with
a poor prognosis. The extent to which this group of patients
needs less intensive immunosuppressive treatment requires
further investigation and also depends on whether extrarenal
inflammation is present.
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In severe cases of ANCA-GN, the risk factors for ESRD
and deaths are largely similar. Therefore, these events serve
as competing end-points. Treating deaths as a censoring
event can lead to underestimation of risk. To overcome this
methodologic problem, we also analyzed cumulative survival
without ESRD and death.With this end-point, 1-year survival
fell from 58% to 48%. However, eGFR ≤15ml/min/1.73m2
continued to be a strong risk factor for this combined end-
point. In cases with such a risk factor, 9 cases developed
ESRD and 3 patients had died during the first year after
being diagnosed with ANCA-GN. During the maintenance
phase, the prognosis was improved, with only 1 of 11
patients progressing to ESRD and no deaths. Notably, this
case of ESRD occurred in patients with an initial eGFR >
15ml/min/1.73m2; however, at this stage, only 1 patient with
a baseline eGFR ≤ 15ml/min/1.73m2 remained in the study
cohort.
In the present study, we also demonstrated that patients
with ANCA-GN and sclerotic histology with ≤10% normal
glomeruli, as indicated by biopsy, had a significantly lower
ESRD-free survival rate. Further, cumulative ESRD-free sur-
vival wasmuch higherwith≤10%normal glomeruli thanwith
an eGFR of ≤15ml/min/1.73m2: 39% versus 15% at 1 year.
Thus, in the present cohort, eGFR ≤15ml/min/1.73m2 was
found to be the risk factor that best defines patients with a
particularly poor prognosis.
Renal survival in our study cohort (i.e., 1-year: 58%) is
approximately within the same range as has been reported
by others. Chen et al. reported 1-year and 2-year ESRD-
free survival rates in 36 patients with sclerotic ANCA-GN
of 69% and 52%, respectively [15]. Berden et al. and Tanna
et al. both reported a 1-year survival rate of 50% in the
sclerotic group [14, 17]. Meanwhile, Chang et al. reported a
substantially poorer outcome of 29% [30]. Estimated GFR
and percentage normal glomeruli are well-documented risk
factors for developing ESRD in patients with ANCA-GN in
general [2, 3, 14]. However, to our knowledge, risk factor
for progression have not yet been thoroughly analyzed,
particularly in patients with sclerotic ANCA-GN. This is
likely due to the small number of patients with sclerotic
histology in earlier reports. Indeed, in a 2017 meta-analysis,
Chen et al. performed a meta-analysis of 16 studies that
reported the prognostic value of histologic classification [15]
and found that the mean number of patients with sclerotic
histology in these studies was 12.7 (range: 1–36). With the
notable exception of the study by Chen et al., which included
36 patients, no other study has analyzed sclerotic histology in
more than 17 patients.
Despite the robustness of our findings, there are some
limitations to our study. First, the sample size is notably small,
with only 23 patients having been included. However, due
to a relatively high number of events, we were nevertheless
able to demonstrate that an eGFR of ≤15ml/min/1.73m2
is a strong and highly statistically significant risk factor
for progression to ESRD in patients with ANCA-GN and
sclerotic histology. Future and preferably prospective studies
are now necessary to confirm our findings and to define
appropriate treatment strategies for this particular group of
patents with ANCA-GN. Second, due to the nature of the
NKBR as a kidney-focused registry, we could not report the
clinical phenotype of ANCA-vasculitis (i.e., granulomatosis
with polyangiitis, microscopic polyangiitis, or real limited
vasculitis) or the extent of extrarenal disease activity, such
as using the Birmingham vasculitis activity score. Third,
although the general principles of treatment of ANCA-GN
in Norway are known and follow standard international
recommendations, we have no data regarding the treatment
regimen used for specific patients in our study cohort [2,
12, 16]. Our observation that the outcomes of patients in
our cohort are comparable to those in previous reports is
indicative of the use of a standard treatment regimen.
5. Conclusions
We have demonstrated that prognosis in patients with
ANCA-GN and sclerotic histology is variable and that risk
stratification by baseline eGFR ≤15ml/min/1.73m2 versus
>15ml/min/1.73m2 is clinically useful. Future prospective
studies are necessary to define the appropriate treatment
strategy for patients with sclerotic histology and baseline of
eGFR ≤15ml/min/1.73m2.
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[20] L. F. Quintana, N. S. Peréz, E. De Sousa et al., “ANCA serotype
and histopathological classification for the prediction of renal
outcome in ANCA-associated glomerulonephritis,” Nephrology
Dialysis Transplantation , vol. 29, no. 9, pp. 1764–1769, 2014.
[21] D. G. Noone, M. Twilt, W. N. Hayes et al., “The new histopatho-
logic classification of ANCA-associated gn and its association
with renal outcomes in childhood,” Clinical Journal of the
American Society of Nephrology, vol. 9, no. 10, pp. 1684–1691,
2014.
[22] E. Nohr, L. Girard, M. James, and H. Benediktsson, “Validation
of a histopathologic classification scheme for antineutrophil
cytoplasmic antibody-associated glomerulonephritis,” Human
Pathology, vol. 45, no. 7, pp. 1423–1429, 2014.
[23] G. S. R. S. N. K. Naidu, A. Sharma, R. Nada et al., “Histopatho-
logical classification of pauci-immune glomerulonephritis and
its impact on outcome,”Rheumatology International, vol. 34, no.
12, pp. 1721–1727, 2014.
[24] S. L. Ford, K. R. Polkinghorne, A. Longano et al., “Histopatho-
logic and clinical predictors of kidney outcomes in ANCA-
associated vasculitis,” American Journal of Kidney Diseases, vol.
63, no. 2, pp. 227–235, 2014.
[25] M. Unlu, S. Kiremitci, A. Ensari et al., “Pauci-immune necrotiz-
ing crescentic glomerulonephritiswith crescentic and fullmoon
extracapillary proliferation: Clinico-pathologic correlation and
follow-up study,” Pathology - Research and Practice, vol. 209, no.
2, pp. 75–82, 2013.
[26] E. Muso, T. Endo, M. Itabashi et al., “Evaluation of the newly
proposed simplified histological classification in Japanese
cohorts of myeloperoxidase-anti-neutrophil cytoplasmic
antibody-associated glomerulonephritis in comparison with
other Asian and European cohorts,” Clinical and Experimental
Nephrology, vol. 17, no. 5, pp. 659–662, 2013.
[27] T. Iwakiri, S. Fujimoto, K. Kitagawa et al., “Validation of a
newly proposed histopathological classification in Japanese
patients with anti-neutrophil cytoplasmic antibody-associated
glomerulonephritis,” BMC Nephrology, vol. 14, article 125, 2013.
[28] M. Hilhorst, B. Wilde, P. Van Breda Vriesman, P. Van Paassen,
and J. W. C. Tervaert, “Estimating renal survival using the
ANCA-associated GN classification,” Journal of the American
Society of Nephrology, vol. 24, no. 9, pp. 1371–1375, 2013.
[29] C. L. Ellis, R. L. Manno, J. P. Havill, L. C. Racusen, and D.
Geetha, “Validation of the new classification of pauci-immune
glomerulonephritis in a United States cohort and its correlation
with renal outcome,” BMC Nephrology, vol. 14, no. 1, article no.
210, 2013.
[30] D.-Y. Chang, L.-H. Wu, G. Liu, M. Chen, C. G. M. Kallenberg,
and M.-H. Zhao, “Re-evaluation of the histopathologic classifi-
cation of ANCA-associated glomerulonephritis: a study of 121
patients in a single center,” Nephrology Dialysis Transplantation
, vol. 27, no. 6, pp. 2343–2349, 2012.
[31] A. Tanna and C. D. Pusey, “The histopathological classification
of ANCA-associated glomerulonephritis comes of age,” The
Journal of Rheumatology, vol. 44, no. 3, pp. 265–267, 2017.
Pathology Research International 7
[32] A. Hinojosa-Azaola and A. Jiménez-González, “Histopatho-
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